BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Pfizer  Limited  submitted  on  25  October  2000  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for VFEND, 
through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  21  September  2000,  this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. B.  van Zwieten-Boot 
Co-Rapporteur: Dr. Eric Abadie 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
A  new  application  was  filed  in  the  following  countries:  Submitted  to  the  FDA  in  November.  The 
product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 28 November 2000. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 16 February 
2001. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 21 
February 2001.  
During  the  meeting  on  27-29  March  2001  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 29 March 2001.  
The company submitted the responses to the CPMP consolidated List of Questions on 28 June 
2001 (Clock started in July CPMP). 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 5 September 2001.  
During the CPMP meeting on 18-20 September 2001, the CPMP agreed on a List of Oustanding 
Issues.  
During  the  CPMP  meeting  on  14  November  2001,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
During  the  meeting  on  11-13  December  2001  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Vfend on 13 December 2001. 
The  CPMP  Opinion  was  forwarded  in  all  official  languages  of  the  European  Commission, 
which adopted the corresponding Decision on 19 March 2002. 
1/1 
EMEA 2004 
 
 
 
 
  
